Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES YEN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1215930268
CMS profile
54506
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,583.25

362 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $7,247.85 357
Education $335.40 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $584.61 24
AstraZeneca Pharmaceuticals LP $483.05 22
GlaxoSmithKline, LLC. $453.75 24
GENZYME CORPORATION $435.69 17
PFIZER INC. $401.67 19
Novartis Pharmaceuticals Corporation $394.12 21
Seagen Inc. $324.25 11
E.R. Squibb & Sons, L.L.C. $320.89 21
Celgene Corporation $299.61 17
Astellas Pharma US Inc $284.25 14
PharmaEssentia USA Corporation $227.66 13
Eisai Inc. $222.85 8
Daiichi Sankyo Inc. $220.31 6
Genentech USA, Inc. $203.48 10
Lilly USA, LLC $200.09 10
Gilead Sciences, Inc. $162.83 13
Amgen Inc. $149.13 10
Myriad Genetic Laboratories, Inc. $149.04 4
SOBI, INC $137.93 6
Pharmacyclics LLC, An AbbVie Company $134.39 6
Takeda Pharmaceuticals U.S.A., Inc. $128.18 7
Pharmacosmos Therapeutics Inc. $112.42 5
MorphoSys, US Inc. $98.19 5
ARRAY BIOPHARMA INC $88.11 5
Bayer Healthcare Pharmaceuticals Inc. $85.10 4
BeiGene USA, Inc. $83.48 3
Regeneron Healthcare Solutions, Inc. $81.72 3
CTI BioPharma Corp. $80.56 4
Karyopharm Therapeutics Inc. $78.56 5
Incyte Corporation $75.68 4
Blueprint Medicines Corporation $75.55 3
Stemline Therapeutics Inc. $67.12 3
Puma Biotechnology, Inc. $63.53 3
Dendreon Pharmaceuticals LLC $59.49 2
Alexion Pharmaceuticals, Inc. $57.16 3
TAIHO ONCOLOGY, INC. $53.08 3
AVEO Pharmaceuticals, Inc. $50.93 2
Merck Sharp & Dohme LLC $41.51 2
EMD Serono, Inc. $41.40 2
Adaptive Biotechnologies Corporation $34.92 1
Mirati Therapeutics, Inc. $33.38 2
Rigel Pharmaceuticals, Inc. $30.38 2
TerSera Therapeutics LLC $28.50 1
AbbVie Inc. $24.67 1
Ipsen Biopharmaceuticals, Inc $23.46 1
Janssen Scientific Affairs, LLC $23.02 1
Boehringer Ingelheim Pharmaceuticals, Inc. $21.62 1
ADC Therapeutics America, Inc. $21.60 1
Pharming Healthcare, Inc. $21.25 1
Emmaus Medical, Inc. $19.80 1
Immunocore Limited $19.62 1
Sumitomo Pharma America, Inc. $19.20 1
Mylan Institutional Inc. $18.27 1
Kite Pharma, Inc. $17.49 1
Novo Nordisk Inc $14.70 1

Page 3 of 8; records 101–150 of 362 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES YEN

NPI 1215930268 · CMS profile ID 54506

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 362 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215930268?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES YEN, NPI 1215930268, CMS profile ID 54506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 362 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215930268?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHARLES YEN, NPI 1215930268, CMS profile ID 54506. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 362 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215930268?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHARLES YEN, NPI 1215930268, CMS profile ID 54506, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 362 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1215930268?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

362 matching records · $7,583.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 362 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 362.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $22.6009/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988384157 CMS
Blueprint Medicines Corporation $29.2809/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051255815 CMS
GlaxoSmithKline, LLC. $7.5709/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001626053 CMS
GlaxoSmithKline, LLC. $24.7309/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001626144 CMS
Pharmacosmos Therapeutics Inc. $16.5909/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046268061 CMS
Amgen Inc. $10.9509/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020551917 CMS
GENZYME CORPORATION $31.7609/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049737509 CMS
Amgen Inc. $4.4509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020551923 CMS
Janssen Biotech, Inc. $25.4709/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988384139 CMS
Janssen Biotech, Inc. $19.1909/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988384209 CMS
Astellas Pharma US Inc $10.2709/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034494455 CMS
E.R. Squibb & Sons, L.L.C. $17.5209/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015955433 CMS
Eisai Inc. $18.5409/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023305115 CMS
Gilead Sciences, Inc. $19.4809/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025834905 CMS
Genentech USA, Inc. $24.8309/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040324817 CMS
Novartis Pharmaceuticals Corporation $11.9309/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993367913 CMS
E.R. Squibb & Sons, L.L.C. $13.4509/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015955437 CMS
Karyopharm Therapeutics Inc. $14.5609/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898377 CMS
Astellas Pharma US Inc $17.9308/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034465441 CMS
Mirati Therapeutics, Inc. $17.8008/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058006867 CMS
PharmaEssentia USA Corporation $26.6808/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059317603 CMS
Genentech USA, Inc. $24.8108/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040324841 CMS
Karyopharm Therapeutics Inc. $13.2108/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056898373 CMS
AstraZeneca Pharmaceuticals LP $25.4508/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011915737 CMS
GENZYME CORPORATION $29.3308/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049737449 CMS
GlaxoSmithKline, LLC. $27.6608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001626775 CMS
Novartis Pharmaceuticals Corporation $15.9608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993367915 CMS
Stemline Therapeutics Inc. $18.6308/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040023083 CMS
Adaptive Biotechnologies Corporation $34.9208/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022979561 CMS
Astellas Pharma US Inc $21.6508/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034437695 CMS
Incyte Corporation $15.8008/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044448327 CMS
Seagen Inc. $57.9908/23/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995662033 CMS
Seagen Inc. $24.8408/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995661911 CMS
Regeneron Healthcare Solutions, Inc. $24.4508/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999557527 CMS
GlaxoSmithKline, LLC. $15.6308/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001634651 CMS
GlaxoSmithKline, LLC. $27.8008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001634697 CMS
AbbVie Inc. $24.6708/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999771985 CMS
Blueprint Medicines Corporation $17.8908/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051255811 CMS
Celgene Corporation $17.1708/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015955413 CMS
Celgene Corporation $1.4908/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015955417 CMS
Celgene Corporation $0.8408/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015955421 CMS
Immunocore Limited $19.6208/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051211081 CMS
TAIHO ONCOLOGY, INC. $20.3608/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055232597 CMS
Novo Nordisk Inc $14.7008/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003161933 CMS
E.R. Squibb & Sons, L.L.C. $9.5308/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015955429 CMS
BeiGene USA, Inc. $25.9808/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051193547 CMS
Blueprint Medicines Corporation $28.3807/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051255807 CMS
Pharmacyclics LLC, An AbbVie Company $20.8107/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998298271 CMS
AstraZeneca Pharmaceuticals LP $25.3607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014303027 CMS
Bayer Healthcare Pharmaceuticals Inc. $15.0607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000502527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,202.90 167
PY2020 $2,153.31 117
PY2021 $6,860.42 228
PY2022 $5,317.50 307
PY2023 $7,583.25 362
PY2024 $10,021.35 322
PY2025 $13,695.47 280

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $342,120.57 36
PY2024 Principal investigator $941,240.71 54
PY2023 Principal investigator $475,669.65 30
PY2022 Principal investigator $508,391.50 54
PY2021 Principal investigator $525,149.41 57
PY2020 Principal investigator $541,397.24 45
PY2019 Principal investigator $57,255.85 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Epizyme, Inc. $750.00 12/19/2025 Non-covered Recipient Entity
Millennium Physicians Association, Pllc
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285146
Principal investigator 1 Epizyme, Inc. $1,000.00 12/19/2025 Non-covered Recipient Entity
Millennium Physicians Association, Pllc
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184285148
Principal investigator 1 ARRAY BIOPHARMA INC $10,338.75 12/17/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228707045
Principal investigator 1 Daiichi Sankyo Inc. $907.20 12/12/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390278
Principal investigator 1 PFIZER INC. $7,500.00 11/04/2025 Non-covered Recipient Entity
Waldron Medical Research Development
ENCORAFENIBBINIMETINIB MASTER PROTOCOL AN OPENLABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIBBINIMETINIB CLINICAL STUDIES No dispute reported 06/30/2026 1228706963
Principal investigator 1 ARRAY BIOPHARMA INC $3,291.42 10/03/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228706965
Principal investigator 1 Karyopharm Therapeutics Inc. $2,700.00 09/24/2025 Non-covered Recipient Entity
Millennium Research & Clinical Development, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664192
Principal investigator 1 ARRAY BIOPHARMA INC $4,050.00 09/17/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228834670
Principal investigator 1 ARRAY BIOPHARMA INC $956.00 09/17/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228834676
Principal investigator 1 ARRAY BIOPHARMA INC $1,500.00 09/17/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228834711
Principal investigator 1 ARRAY BIOPHARMA INC $3,989.88 09/17/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228834717
Principal investigator 1 ARRAY BIOPHARMA INC $6,470.05 09/17/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228834722
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $12,743.80 09/02/2025 Non-covered Recipient Entity
Waldron Medical R And D
A Phase 3b randomized study of lenalidomide (CC-5013)plus rituximab maintenance therapy followed by lenalidomide singe-agent maintenance vs. rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma No dispute reported 06/30/2026 1235991877
Principal investigator 1 PFIZER INC. $28,673.76 07/13/2025 Non-covered Recipient Entity
Millennium Research Clinical Development
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228721523
Principal investigator 1 PFIZER INC. $18,755.10 07/13/2025 Non-covered Recipient Entity
Millennium Research Clinical Development
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228721525
Principal investigator 1 Karyopharm Therapeutics Inc. $1,440.00 07/08/2025 Non-covered Recipient Entity
Millennium Research & Clinical Development, LLC
A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1246664194
Principal investigator 1 Daiichi Sankyo Inc. $189.30 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390264
Principal investigator 1 Daiichi Sankyo Inc. $631.00 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390266
Principal investigator 1 Daiichi Sankyo Inc. $631.00 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390268
Principal investigator 1 Daiichi Sankyo Inc. $631.00 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390270
Principal investigator 1 Daiichi Sankyo Inc. $631.00 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390272
Principal investigator 1 Daiichi Sankyo Inc. $631.00 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390274
Principal investigator 1 Daiichi Sankyo Inc. $631.00 06/26/2025 Non-covered Recipient Entity
Waldron Medical Research And Development, Llc
DS8201-A-U302 No dispute reported 06/30/2026 1223390276
Principal investigator 1 Epizyme, Inc. $2,500.00 06/16/2025 Non-covered Recipient Entity
Texas Oncology Kingwood North
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282311
Principal investigator 1 Epizyme, Inc. $500.00 06/16/2025 Non-covered Recipient Entity
Texas Oncology Kingwood North
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282313
Principal investigator 1 Epizyme, Inc. $500.00 06/16/2025 Non-covered Recipient Entity
Texas Oncology Kingwood North
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282315
Principal investigator 1 Epizyme, Inc. $2,000.00 06/16/2025 Non-covered Recipient Entity
Texas Oncology Kingwood North
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma No dispute reported 06/30/2026 1184282317
Principal investigator 1 PFIZER INC. $28,673.76 06/15/2025 Non-covered Recipient Entity
Millennium Research Clinical Development
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228841534
Principal investigator 1 PFIZER INC. $28,673.76 05/18/2025 Non-covered Recipient Entity
Millennium Research Clinical Development
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228841540
Principal investigator 1 ARRAY BIOPHARMA INC $27,487.50 05/01/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND D
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228849956
Principal investigator 1 ARRAY BIOPHARMA INC $5,000.00 04/23/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND D
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228849422
Principal investigator 1 ARRAY BIOPHARMA INC $700.00 04/23/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND D
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228849485
Principal investigator 1 PFIZER INC. $86,021.28 04/22/2025 Non-covered Recipient Entity
Millennium Research Clinical Development
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228841524
Principal investigator 1 Genentech, Inc. $17,073.00 02/19/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
AcceleRET Lung Study of Pralsetinib for 1L RET Fusion positive Metastatic NSCLC No dispute reported 06/30/2026 1211683866
Principal investigator 1 PFIZER INC. $28,673.76 01/26/2025 Non-covered Recipient Entity
Millennium Research Clinical Development
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228841518
Principal investigator 1 ARRAY BIOPHARMA INC $5,276.25 01/22/2025 Non-covered Recipient Entity
WALDRON MEDICAL RESEARCH AND DEVELOPMENT LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228855046